Literature DB >> 14625670

Dosing of medications in morbidly obese patients in the intensive care unit setting.

Brian L Erstad1.   

Abstract

OBJECTIVE: To derive recommendations for the dosing of commonly used medications in the morbidly obese patient in the ICU. DATA SOURCES: Articles were obtained through computerized searches involving MEDLINE. The bibliographies of retrieved publications and textbooks were reviewed for additional references. STUDY SELECTION: All studies involving the pharmacokinetics or pharmacodynamics of medications in obese subjects or patients. DATA EXTRACTION: The emphasis was on studies involving morbidly obese patients but, in the absence of such data, investigations involving lesser forms of obesity were extracted. DATA SYNTHESIS: There is a paucity of data upon which to make recommendations for dosing commonly used medications in the morbidly obese patient in the ICU, although recommendations were provided based on the available information.
CONCLUSIONS: There is clearly a need for more investigations involving dosing regimens of medications in the morbidly obese population. Until such studies are available, the clinician must try to derive the best dosing regimens for medications based on the limited pharmacokinetic data available for some agents and clinical judgement.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14625670     DOI: 10.1007/s00134-003-2059-6

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  59 in total

Review 1.  The meaning and measurement of lean body mass.

Authors:  R Roubenoff; J J Kehayias
Journal:  Nutr Rev       Date:  1991-06       Impact factor: 7.110

2.  Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study.

Authors:  M B Bracken; M J Shepard; T R Holford; L Leo-Summers; E F Aldrich; M Fazl; M Fehlings; D L Herr; P W Hitchon; L F Marshall; R P Nockels; V Pascale; P L Perot; J Piepmeier; V K Sonntag; F Wagner; J E Wilberger; H R Winn; W Young
Journal:  JAMA       Date:  1997-05-28       Impact factor: 56.272

3.  Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery.

Authors:  M J Kovacs; K Weir; K MacKinnon; M Keeney; W F Brien; M K Cruickshank
Journal:  Thromb Res       Date:  1998-08-01       Impact factor: 3.944

4.  Pharmacokinetics of ranitidine in morbidly obese women.

Authors:  R L Davis; R W Quenzer; H P Bozigian; C W Warner
Journal:  DICP       Date:  1990-11

5.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

6.  Lidocaine disposition in obesity.

Authors:  D R Abernethy; D J Greenblatt
Journal:  Am J Cardiol       Date:  1984-04-01       Impact factor: 2.778

7.  Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient.

Authors:  A E Schwartz; R S Matteo; E Ornstein; J D Halevy; J Diaz
Journal:  Anesth Analg       Date:  1992-04       Impact factor: 5.108

8.  Obesity and post-operative pain.

Authors:  C S Rand; J M Kuldau; R L Yost
Journal:  J Psychosom Res       Date:  1985       Impact factor: 3.006

9.  Phenytoin disposition in obesity. Determination of loading dose.

Authors:  D R Abernethy; D J Greenblatt
Journal:  Arch Neurol       Date:  1985-05

10.  Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects.

Authors:  R L Yost; H Derendorf
Journal:  Ther Drug Monit       Date:  1986       Impact factor: 3.681

View more
  28 in total

1.  Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus.

Authors:  Christophe Bardin; Estelle Nobecourt; Etienne Larger; François Chast; Jean-Marc Treluyer; Saik Urien
Journal:  Eur J Clin Pharmacol       Date:  2012-01-25       Impact factor: 2.953

2.  Quantitative peptidomics in mice: effect of cocaine treatment.

Authors:  Fa-Yun Che; Ilona Vathy; Lloyd D Fricker
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

Review 3.  Designing drug regimens for special intensive care unit populations.

Authors:  Brian L Erstad
Journal:  World J Crit Care Med       Date:  2015-05-04

4.  The Daniel K. Inouye College of Pharmacy Scripts: Obesity: The Drug Dose Debate.

Authors:  Cherie Chu; Louis Lteif; Nicole Young
Journal:  Hawaii J Med Public Health       Date:  2017-06

5.  Pharmacokinetics and drug dosing in obese children.

Authors:  Jennifer G Kendrick; Roxane R Carr; Mary H H Ensom
Journal:  J Pediatr Pharmacol Ther       Date:  2010-04

6.  Unanswered questions about VTE prophylaxis in critically ill obese patients.

Authors:  Abigail Dee Antigua; Stacy A Voils
Journal:  Intensive Care Med       Date:  2016-07-13       Impact factor: 17.440

7.  Measurement of glomerular filtration rate in obese patients: pitfalls and potential consequences on drug therapy.

Authors:  Grégoire Wuerzner; Murielle Bochud; Vittorio Giusti; Michel Burnier
Journal:  Obes Facts       Date:  2011-06-06       Impact factor: 3.942

Review 8.  Therapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology.

Authors:  Jennifer H Martin; Mohamed Saleem; David Looke
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

9.  The eradication of Helicobacter pylori is affected by body mass index (BMI).

Authors:  Mohamed Abdullahi; Bruno Annibale; Danila Capoccia; Roberto Tari; Edith Lahner; John Osborn; Frida Leonetti; Carola Severi
Journal:  Obes Surg       Date:  2008-04-29       Impact factor: 4.129

10.  Obesity Is Not Associated with Antimicrobial Treatment Failure for Intra-Abdominal Infection.

Authors:  Zachary C Dietch; Therese M Duane; Charles H Cook; Patrick J O'Neill; Reza Askari; Lena M Napolitano; Nicholas Namias; Christopher M Watson; Daniel L Dent; Brandy L Edwards; Puja M Shah; Christopher A Guidry; Stephen W Davies; Rhett N Willis; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2016-03-30       Impact factor: 2.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.